Kymera Therapeutics is recalibrating its development strategy with a new partnership with Gilead Sciences to co-develop oral molecular glue degraders targeting CDK2, an enzyme associated with tumor growth. This deal could yield up to $750 million and marks validation for Kymera's targeted protein degradation platform. Concurrently, Sanofi is advancing a different candidate, KT-485, in lieu of KT-474, signaling strategic portfolio adjustments. These moves underscore Kymera's repositioning amid competition and highlight the growing interest in protein degradation therapies in oncology.